MAGE-A1-specific T cell receptor-transduced autologous T-cell therapy(SignalOne Bio)

MAGE-A1特异性T细胞受体转导自体T细胞治疗（SignalOne-Bio）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMAGE-A1-specific T cell receptor-transduced autologous T-cell therapy(SignalOne Bio)
Drug Alias NameFH-MagIC TCR-T cell therapyMAGE-A1-specific T cell receptor-transduced autologous CD8+ and CD4+ T-cellsMAGE-A1-specific TCR-transduced autologous T-cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSignalOne Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A